Amazing novel approach to treating cancer if it works. I'm more excited about VX 765 and it's more immediate prospects for clinical use if proof of concept Phase 2 clinical trials prove positive in treating HIV.(I suspect Vertex new CMO who is an HIV expert, and is taking over for retiring Bob Kaufman this summer, is working with Warner Greene to plan this Phase 2A trial).
Wall Street needs to see the TRAFFIC and TRANSPORT clinical trial data before rewarding VRTX, but when positive 809/770 data supporting the NDA filing is announced some time in the next 8 weeks, Vertex will likely start to be valued for the expected revenue growth for treating the majority of CF patients. IMO after that, management will reveal it's plans for R&D going forward for all it's early pipeline assets (in addition to CF treatments for 508 heterozygotes), including VX 765 to treat HIV, it's chronic MS remyelination drug, and this stem cell oncology program. (Management knows the cash flow from CF is what Wall Street is fixated on, and they do not want to distract analysts with new programs until they reward Vertex for the likely success of 809/770 suggested by management's new manufacturing facility for continuous production of 809/770 tablets in Boston, the hiring currently underway of the expanded international commercial team to market 809/770, and the work underway in the development of these preclinical pipeline assets, which could only be funded by the huge cash flow expected from the imminent approval of 809/770 and the expanded indications for Ivacaftor monotherapy.
The Biotech sector will likely come back to life very quickly with the announcement of positive TRAFFIC and TRANSPORT data and the NDA filings for 809/770 treatment of CF in 508d homozygotes.
Q, I absolutely agree with you. Without foreseeing revenues flowing from 809 sales, they would not set up a research center overseas to engage in rather speculative research areas. Traffic and Transport are double-blind trials, so that they would not know who is taking placebo and who is taking the drugs, but they keep the records of clinical signs of all participants, from which you can qualitatively infer the outcome.
From the stated responsibilities of the positions to be created, one can surmise that Vertex already has a cancer program in place, and its objective is to transform cancer stem cells back to a non-growing, harmless tissue. It is easy to kill cancer cells, but in doing so you damage lots of normal cells. Using small molecules it may be possible to trigger re-differentiation of cancer cells without harming other normal cells. Knowledge of stem cell differentiation would be helpful for that purpose.
Third, what's your impressions of this new position being recruited on the career page of the Vertex web site? I find this new interest in developing a research center in Shanghhai for translational research in Stem Cell/ regenerative medicine by Vertex,a sign of confidence in the near term for commercial success of the CF drugs to foot the cost of this new long term research commitment.
"We're looking for a seasoned Research Fellow to help establish a new stem cell based discovery platform in its new R&D center in Shanghai, China. This exciting opportunity calls for someone who has deep and broad expertise in the area of stem cell biology, iPS differentiation and disease modeling, with at least 7-10 years of post-doctoral experience with demonstrated success in project leadership and advancing key scientific understanding of the stem cell field. Superior skills in organization and communication are required.
Describe the essential, day-to-day job duties; include specifics around the project, deliverables, accountabilities, and timelines with which each job responsibility is tied and highlight the different contacts, both internal and external, with which these duties will require interaction.
You will be responsible for building a stem cell discovery platform, and leading a group of biologists targeting cancer stem cells and screening for compounds promoting tissue regeneration. Reporting to the SVP and General Manager of China, you would be responsible for project and external collaboration leadership and you would be a key contributor to the development of our regenerative medicine strategy.
- Provides the scientific and technical lead role for stem cell platform at the Vertex Pharmaceuticals China site
- Hires, manages, mentors and develops Ph.D. and M.Sc./B.Sc. level staff, initially through a partnership with a CRO
- Proposes, implements and leads new and innovative conceptual/seeds projects and lead optimization projects"
finance news women plus one male analyst. They talked about an upcoming great catalyst for VRTX, the most important biotech binary event this year, maybe ever. Said result could cause it to soar to 100 or drop to 40. What's this all about, in 50 words or less, or good reference? Thanks.
LOL. Nostradamus. Cracked me up. But I think he might mean that the sector has a lot more down to go, way outside the channel. There seems to be a rotation out of future earnings to current earnings, even safe bonds, so if this is what he meant he might turn out to be right.
Q, thank you for posting this. CFO also said in the cc several weeks ago that a commercial structure for sales of 809 has been in place.
the British Medical Journal has a very negative assessment on Tamiflu:
"Important benefits have been overestimated and harms under-reported. In particular, the review found no compelling evidence to support claims that oseltamivir reduces the risk of complications of influenza, such as pneumonia and hospital admission, claims that were used to justify international stockpiling of the drug."
will this increase chances for VX-787?
biotech is in real trouble, along with this tech bubble that VCs feed and then dump on the mutual funds.